Developer docs
API playgroundTry for free, no card

Search company profiles

Niowave

Full company profile

uuid00032fm

Namestring
Niowave
Legal namestring
Niowave, Inc.
Websiteurl
niowaveinc.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Niowave, Inc. is a privately-held medical radioisotope manufacturer founded in 2005 and headquartered in Lansing, Michigan. The company produces Actinium-225 (Ac-225) and Yttrium-90 (Y-90) using proprietary superconducting electron linear accelerators paired with in-house radiochemistry and cGMP-compliant processing, including a Radium-226 acquisition and recycling program achieving greater than 99% material recovery per cycle. Niowave operates what the company describes as the only private-sector platform in the world that both designs and operates superconducting linear accelerators integrated with downstream radiochemical separation, purification, and packaging within hot-cell infrastructure. The company's primary products—Ac-225 for targeted alpha therapy and Y-90 for liver cancer therapy—are manufactured at centralized Lansing facilities that include a recently expanded production site and a new $75 million facility (groundbroken May 21, 2026) designed to house six superconducting linear accelerators and enable production beyond 175 Ci per year when operational in 2028.

Niowave's commercial model centers on long-term bilateral supply agreements with global pharmaceutical companies and clinical-stage radiopharmaceutical biotechs. Anchor customers include AstraZeneca (supply agreement expanded to a 10-year commitment in December 2025) and Novartis (long-term global supply agreement announced February 2026), complemented by supply contracts with Ratio Therapeutics, Fusion Pharmaceuticals, Aktis Oncology, and a 50/50 strategic co-development collaboration with Aptevo Therapeutics covering up to three radiopharmaceutical oncology programs. Pricing is negotiated bilaterally and not publicly disclosed. Revenue mechanics combine multi-year recurring supply contracts with outcome-linked co-development economics; in May 2026, Niowave also made its first equity investment in a therapeutic developer (an initial 7.9% stake in Aptevo, potentially up to 19.99% via warrants), signaling a vertical extension from pure isotope supply into shared therapeutic economics.

The company employs approximately 180 people as of January 2026 and is scaling headcount further via the new facility (approximately 70 additional highly skilled jobs expected). Niowave holds FDA Drug Master File acceptance for cGMP-grade Ac-225 (filed 2023), ISO 13485 certification, and expanded NRC licensing, and is supported by state-level economic development funding including a $500,000 Michigan EDC grant (2023) and a $2.1 million Michigan DOT infrastructure grant (2026). Capital formation to date has been primarily through exempt securities offerings (most recently a $2,000,250 proposed / $1,699,250 sold Form D filing in December 2021, plus a $2,999,500 round in August 2019), supplemented by federal and state grants and the Aptevo equity investment.

Short descriptiontext

Niowave is a private Lansing, Michigan-based manufacturer of medical radioisotopes—primarily Actinium-225 and Yttrium-90—produced via proprietary superconducting linear accelerators. It supplies global pharmaceutical and clinical-stage radiopharmaceutical biotech customers under long-term cGMP supply agreements and co-development collaborations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLansing, United States
HQ citystring
Lansing
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical radioisotope manufacturing, actinium-225 production, radiopharmaceutical isotope supply, superconducting accelerator technology, nuclear medicine isotopes
Industry1 code
PRIMARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Medical Radioisotope Manufacturing
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Long-term isotope supply agreements
TypeSubscription Recurring
Description

Niowave generates revenue through multi-year commercial supply agreements with global pharmaceutical and biotechnology customers (e.g., 10-year deal with AstraZeneca, long-term deal with Novartis) for cGMP Actinium-225 and Yttrium-90. Contracts specify scalable volumes tied to the customer's pipeline progression. Financial terms are not publicly disclosed.

fiercepharma.com
2Strategic co-development collaborations
TypeLicensing Royalties
Description

Niowave enters 50/50 strategic collaborations (e.g., with Aptevo for up to three radiopharmaceutical programs), contributing isotopes, manufacturing, and capital (initial 7.9% equity stake, up to 19.99% via warrants) in exchange for shared development economics and equity upside.

investing.com
3Private exempt securities offerings
TypeTransaction Fee
Description

Niowave has raised capital via exempt securities offerings (e.g., SEC Form D filing for total proposed $2,000,250 with $1,699,250 sold) including equity and pooled investment fund interests, consistent with a privately-held growth-stage company funding operations and expansion.

sec.gov
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
Pricing details4 tiers
1Custom long-term Ac-225 supply contracts with major pharma
ModelOtherBilling cadenceMulti-year contract
Notes

Financial terms not disclosed; scalable supply tied to customer's radioligand/radioconjugate pipeline progression.

fiercepharma.com
210-year capacity-secured Ac-225 supply (AstraZeneca)
ModelOtherBilling cadenceMulti-year contract
Notes

AstraZeneca expanded its existing supply agreement to a 10-year commitment, exercising option to increase capacity.

thepharmaletter.com
3Strategic co-development + equity (Aptevo 50/50)
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

Up to three radiopharmaceutical programs; Niowave made at-the-market equity investment representing 7.9% ownership at closing, with potential to reach 19.99% via warrant exercises at premium.

investing.com
4Private exempt securities offering
ModelUnit PricingBilling cadencePay-as-you-go
Notes

SEC Form D filing, total proposed amount $2,000,250 USD; amount sold $1,699,250 USD (equity, pooled investment fund interests, other securities).

sec.gov
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Niowave manufactures and supplies high-purity, cGMP-compliant medical radioisotopes — primarily Actinium-225 (Ac-225) and Yttrium-90 (Y-90) — using proprietary superconducting linear accelerators paired with in-house radiochemistry and hot-cell processing. The isotopes are sold under multi-year bilateral supply agreements to global pharmaceutical and biotechnology customers developing targeted alpha therapy and radioligand therapy for cancer, with the company also entering 50/50 strategic co-development collaborations (e.g., Aptevo) and operating a proprietary radium-226 acquisition/recovery program that supplies feedstock for Ac-225 production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 10-year long-term supply agreement secured with AstraZeneca for Actinium-225 (Dec 2025)
+4 more records
Product overview1 text field

Niowave operates a vertically integrated, single-platform production architecture rather than a suite of independent products: its proprietary superconducting linear accelerators, paired with in-house radiochemistry and cGMP-compliant hot-cell processing, form a unified system that converts acquired Radium-226 into finished medical radioisotopes. The principal commercial outputs of this platform are Actinium-225 (Ac-225), the company's flagship alpha-emitting isotope for targeted alpha therapy in oncology, and Yttrium-90 (Y-90), a beta-emitting isotope used in liver cancer therapy that also served as the operational and radiochemical foundation for the Ac-225 program. Radiopharmaceutical supply agreements with Novartis, AstraZeneca, Ratio Therapeutics, and Aptevo, as well as the new $75 million Lansing facility slated to come online in 2028, are layered on top of this accelerator-plus-radiochemistry platform.

Product and service2 records
1Actinium-225 (Ac-225)
CategoryMedical Radioisotope — Alpha Emitter (Therapeutic)
Description

High-purity, cGMP-compliant Actinium-225 alpha-emitting medical radioisotope produced via Niowave's proprietary superconducting linear accelerator platform and in-house radiochemistry. Used by global pharmaceutical developers and clinical partners for targeted alpha therapy (TAT) in oncology, including prostate, neuroendocrine, leukemia, and other difficult-to-treat cancers.

2Yttrium-90 (Y-90)
CategoryMedical Radioisotope — Beta Emitter (Therapeutic)
Description

High-purity Yttrium-90 beta-emitting medical radioisotope produced from radioactive decay of Strontium-90 and separated/purified using Niowave's proprietary radiochemical processing platform. Used in targeted liver cancer therapies and as the foundation for Niowave's Ac-225 production capabilities.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Supply agreement for cGMP Actinium-225 to support Ratio Therapeutics' development of targeted radiotherapeutics, including ongoing clinical trial activities and future program advancement. Ratio is a clinical-stage pharma company headquartered in Boston developing precision radiopharmaceuticals for solid tumors.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Aptevo contributes multispecific antibody platform assets (initial Nectin-4 target); Niowave supplies Actinium-225 and additional radioisotopes plus manufacturing capabilities. Niowave also made an at-the-market equity investment in Aptevo at closing (initial 7.9% ownership, with potential to reach up to 19.99% via warrant exercises).

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-21
Description

General contractor leading construction of Niowave's new $75M production facility in Lansing, MI (groundbroken May 21, 2026), in collaboration with Colliers Engineering & Design. Site expected to be operational in 2028.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-21
Description

Engineering and design partner collaborating with The Christman Company on construction of Niowave's new $75M Lansing production facility.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Long-term global supply agreement for Actinium-225 to support Novartis's growing portfolio of radioligand therapies (RLT) for difficult-to-treat cancers. Financial terms undisclosed. Novartis subsequently used Niowave's Ac-225 supply to support its experimental actinium-based drug program in prostate cancer (101-patient trial). Nova's investment in a new Niowave manufacturing facility was triggered in part by this agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Niowave was spun off from MSU's NSCL in 2005; founder Dr. Terry Grimm spent 13 years at NSCL as Senior Physicist and Adjunct Professor, and the company's early superconducting linac work built on MSU research. Niowave describes active collaboration with 'top-tier universities and research institutions' across isotope application.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-19
Description

Existing supply agreement expanded to a 10-year commitment for Actinium-225 following AstraZeneca's decision to exercise its option to increase capacity. Secures reliable, scalable supply for AstraZeneca's growing radioconjugate pipeline targeting prostate and other difficult-to-treat cancers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Multi-year supply agreement for Actinium-225 established during Niowave's 2022-2025 strategic partnership expansion phase, supporting Fusion's radiopharmaceutical development pipeline.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Multi-year supply agreement for Actinium-225 established during Niowave's 2022-2025 strategic partnership expansion phase, supporting Aktis's targeted radiopharmaceutical oncology pipeline.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S.-based commercial producer of medical radioisotopes (notably Mo-99/Tc-99m) using accelerator and neutron-capture technology. Most directly comparable U.S. private radioisotope producer competing for the same domestic, cGMP-grade supply contracts with pharma and imaging customers.

TypeDirect peer
Description

U.S. company producing medical radioisotopes including Ac-225 and lutetium-177 using fusion-based neutron sources. Direct competitor in cGMP Ac-225 supply targeting the same radioligand therapy and targeted alpha therapy developers.

TypeDirect peer
Description

Germany-based medical radioisotope producer (notably Lu-177 and Ac-225) supplying global pharma and radiopharma developers. Direct international peer in cGMP-grade therapeutic radioisotope supply for cancer applications.

TypeBroad incumbent
Description

Global nuclear medicine leader producing a broad portfolio of diagnostic and therapeutic radioisotopes. Overlaps with Niowave in cGMP medical isotope supply but operates at much greater scale across Mo-99, I-131, Lu-177 and other isotopes.

TypeBroad incumbent
Description

Diversified medtech giant with a substantial radiopharma business spanning PET tracers, SPECT agents and emerging therapeutic isotopes. Broad incumbent offering isotope production as part of a much wider imaging and pharmaceutical portfolio.

TypeBroad incumbent
Description

Public radiopharmaceutical company specializing in diagnostic imaging agents and increasingly therapeutic radioligands. Comparable end-customer focus in oncology nuclear medicine, though primarily a developer/marketer rather than a pure-play isotope supplier.

TypeEmerging player
Description

Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents using Ac-225, Lu-177 and other isotopes. Significant overlap as a downstream buyer/developer of medical radioisotopes, positioning Telix as both customer and adjacent competitor in targeted alpha therapy.

TypeEmerging player
Description

Clinical-stage radioconjugate developer (now part of AstraZeneca) that has been a Niowave Ac-225 supply customer. Represents the emerging radiopharma developer peer that depends on suppliers like Niowave for isotope feedstock.

TypeBroad incumbent
Description

Major pharma with an established radioligand therapy franchise (Xofigo / Ra-223) and growing investment in targeted radionuclide therapies. A large incumbent competing for the same clinical and commercial therapeutic isotope demand.

TypeDirect peer
Description

Belgium-based supplier of particle accelerators and radioisotope production solutions to nuclear medicine and radiopharma producers. Overlaps with Niowave in accelerator-based isotope production technology and end-customer relationships in the medical radioisotope supply chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Niowave

Medical Radioisotope Manufacturingniowaveinc.com

Niowave is a private Lansing, Michigan-based manufacturer of medical radioisotopes—primarily Actinium-225 and Yttrium-90—produced via proprietary superconducting linear accelerators. It supplies global pharmaceutical and clinical-stage radiopharmaceutical biotech customers under long-term cGMP supply agreements and co-development collaborations.

What Niowave does

Niowave, Inc. is a privately-held medical radioisotope manufacturer founded in 2005 and headquartered in Lansing, Michigan. The company produces Actinium-225 (Ac-225) and Yttrium-90 (Y-90) using proprietary superconducting electron linear accelerators paired with in-house radiochemistry and cGMP-compliant processing, including a Radium-226 acquisition and recycling program achieving greater than 99% material recovery per cycle. Niowave operates what the company describes as the only private-sector platform in the world that both designs and operates superconducting linear accelerators integrated with downstream radiochemical separation, purification, and packaging within hot-cell infrastructure. The company's primary products—Ac-225 for targeted alpha therapy and Y-90 for liver cancer therapy—are manufactured at centralized Lansing facilities that include a recently expanded production site and a new $75 million facility (groundbroken May 21, 2026) designed to house six superconducting linear accelerators and enable production beyond 175 Ci per year when operational in 2028.

Niowave's commercial model centers on long-term bilateral supply agreements with global pharmaceutical companies and clinical-stage radiopharmaceutical biotechs. Anchor customers include AstraZeneca (supply agreement expanded to a 10-year commitment in December 2025) and Novartis (long-term global supply agreement announced February 2026), complemented by supply contracts with Ratio Therapeutics, Fusion Pharmaceuticals, Aktis Oncology, and a 50/50 strategic co-development collaboration with Aptevo Therapeutics covering up to three radiopharmaceutical oncology programs. Pricing is negotiated bilaterally and not publicly disclosed. Revenue mechanics combine multi-year recurring supply contracts with outcome-linked co-development economics; in May 2026, Niowave also made its first equity investment in a therapeutic developer (an initial 7.9% stake in Aptevo, potentially up to 19.99% via warrants), signaling a vertical extension from pure isotope supply into shared therapeutic economics.

The company employs approximately 180 people as of January 2026 and is scaling headcount further via the new facility (approximately 70 additional highly skilled jobs expected). Niowave holds FDA Drug Master File acceptance for cGMP-grade Ac-225 (filed 2023), ISO 13485 certification, and expanded NRC licensing, and is supported by state-level economic development funding including a $500,000 Michigan EDC grant (2023) and a $2.1 million Michigan DOT infrastructure grant (2026). Capital formation to date has been primarily through exempt securities offerings (most recently a $2,000,250 proposed / $1,699,250 sold Form D filing in December 2021, plus a $2,999,500 round in August 2019), supplemented by federal and state grants and the Aptevo equity investment.

Niowave firmographics

Firmographics
Name
Niowave
Legal name
Niowave, Inc.
Website
https://niowaveinc.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Niowave is a private Lansing, Michigan-based manufacturer of medical radioisotopes—primarily Actinium-225 and Yttrium-90—produced via proprietary superconducting linear accelerators. It supplies global pharmaceutical and clinical-stage radiopharmaceutical biotech customers under long-term cGMP supply agreements and co-development collaborations.
Ownership category
akta.pro rank

Niowave industry classification

Industry
Product category
Medical Radioisotope Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Medical radioisotope manufacturing
  • Actinium-225 production
  • Radiopharmaceutical isotope supply
  • Superconducting accelerator technology
  • Nuclear medicine isotopes

Where Niowave is headquartered

Location

Headquarters

HQ city
Lansing
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Niowave business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Infrastructure, Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Long-term isotope supply agreements: Niowave generates revenue through multi-year commercial supply agreements with global pharmaceutical and biotechnology customers (e.g., 10-year deal with AstraZeneca, long-term deal with Novartis) for cGMP Actinium-225 and Yttrium-90. Contracts specify scalable volumes tied to the customer's pipeline progression. Financial terms are not publicly disclosed.
  2. Strategic co-development collaborations: Niowave enters 50/50 strategic collaborations (e.g., with Aptevo for up to three radiopharmaceutical programs), contributing isotopes, manufacturing, and capital (initial 7.9% equity stake, up to 19.99% via warrants) in exchange for shared development economics and equity upside.
  3. Private exempt securities offerings: Niowave has raised capital via exempt securities offerings (e.g., SEC Form D filing for total proposed $2,000,250 with $1,699,250 sold) including equity and pooled investment fund interests, consistent with a privately-held growth-stage company funding operations and expansion.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom long-term Ac-225 supply contracts with major pharma
OtherMulti-year contract10-year capacity-secured Ac-225 supply (AstraZeneca)
Outcome Based/ PerformanceMulti-year contractStrategic co-development + equity (Aptevo 50/50)
Unit PricingPay-as-you-goPrivate exempt securities offering

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Niowave product offering

Product offering

Core offering

Niowave manufactures and supplies high-purity, cGMP-compliant medical radioisotopes — primarily Actinium-225 (Ac-225) and Yttrium-90 (Y-90) — using proprietary superconducting linear accelerators paired with in-house radiochemistry and hot-cell processing. The isotopes are sold under multi-year bilateral supply agreements to global pharmaceutical and biotechnology customers developing targeted alpha therapy and radioligand therapy for cancer, with the company also entering 50/50 strategic co-development collaborations (e.g., Aptevo) and operating a proprietary radium-226 acquisition/recovery program that supplies feedstock for Ac-225 production.

Product overview

Niowave operates a vertically integrated, single-platform production architecture rather than a suite of independent products: its proprietary superconducting linear accelerators, paired with in-house radiochemistry and cGMP-compliant hot-cell processing, form a unified system that converts acquired Radium-226 into finished medical radioisotopes. The principal commercial outputs of this platform are Actinium-225 (Ac-225), the company's flagship alpha-emitting isotope for targeted alpha therapy in oncology, and Yttrium-90 (Y-90), a beta-emitting isotope used in liver cancer therapy that also served as the operational and radiochemical foundation for the Ac-225 program. Radiopharmaceutical supply agreements with Novartis, AstraZeneca, Ratio Therapeutics, and Aptevo, as well as the new $75 million Lansing facility slated to come online in 2028, are layered on top of this accelerator-plus-radiochemistry platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Actinium-225 (Ac-225) High-purity, cGMP-compliant Actinium-225 alpha-emitting medical radioisotope produced via Niowave's proprietary superconducting linear accelerator platform and in-house radiochemistry. Used by global pharmaceutical developers and clinical partners for targeted alpha therapy (TAT) in oncology, including prostate, neuroendocrine, leukemia, and other difficult-to-treat cancers.
  • Yttrium-90 (Y-90) High-purity Yttrium-90 beta-emitting medical radioisotope produced from radioactive decay of Strontium-90 and separated/purified using Niowave's proprietary radiochemical processing platform. Used in targeted liver cancer therapies and as the foundation for Niowave's Ac-225 production capabilities.

Quantifiable outcome

  • 10-year long-term supply agreement secured with AstraZeneca for Actinium-225 (Dec 2025)
  • +4 more outcomes

Companies that use Niowave

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Niowave technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Niowave partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

  • Ratio TherapeuticscoreStrategic or Co-development Partner · 16 June 2026Supply agreement for cGMP Actinium-225 to support Ratio Therapeutics' development of targeted radiotherapeutics, including ongoing clinical trial activities and future program advancement. Ratio is a clinical-stage pharma company headquartered in Boston developing precision radiopharmaceuticals for solid tumors.
  • Aptevo TherapeuticsflagshipStrategic or Co-development Partner · 27 May 202650/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Aptevo contributes multispecific antibody platform assets (initial Nectin-4 target); Niowave supplies Actinium-225 and additional radioisotopes plus manufacturing capabilities. Niowave also made an at-the-market equity investment in Aptevo at closing (initial 7.9% ownership, with potential to reach up to 19.99% via warrant exercises).
  • The Christman CompanyminorImplementation/ SI/ Consulting Partner · 21 May 2026General contractor leading construction of Niowave's new $75M production facility in Lansing, MI (groundbroken May 21, 2026), in collaboration with Colliers Engineering & Design. Site expected to be operational in 2028.
  • Colliers Engineering & DesignminorImplementation/ SI/ Consulting Partner · 21 May 2026Engineering and design partner collaborating with The Christman Company on construction of Niowave's new $75M Lansing production facility.
  • NovartisflagshipStrategic or Co-development Partner · 11 February 2026Long-term global supply agreement for Actinium-225 to support Novartis's growing portfolio of radioligand therapies (RLT) for difficult-to-treat cancers. Financial terms undisclosed. Novartis subsequently used Niowave's Ac-225 supply to support its experimental actinium-based drug program in prostate cancer (101-patient trial). Nova's investment in a new Niowave manufacturing facility was triggered in part by this agreement.
  • Michigan State University (MSU) — National Superconducting Cyclotron Laboratory (NSCL)coreStrategic or Co-development Partner · 1 January 2026Niowave was spun off from MSU's NSCL in 2005; founder Dr. Terry Grimm spent 13 years at NSCL as Senior Physicist and Adjunct Professor, and the company's early superconducting linac work built on MSU research. Niowave describes active collaboration with 'top-tier universities and research institutions' across isotope application.
  • AstraZenecaflagshipStrategic or Co-development Partner · 19 December 2025Existing supply agreement expanded to a 10-year commitment for Actinium-225 following AstraZeneca's decision to exercise its option to increase capacity. Secures reliable, scalable supply for AstraZeneca's growing radioconjugate pipeline targeting prostate and other difficult-to-treat cancers.
  • Fusion PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2023Multi-year supply agreement for Actinium-225 established during Niowave's 2022-2025 strategic partnership expansion phase, supporting Fusion's radiopharmaceutical development pipeline.
  • Aktis OncologycoreStrategic or Co-development Partner · 1 January 2023Multi-year supply agreement for Actinium-225 established during Niowave's 2022-2025 strategic partnership expansion phase, supporting Aktis's targeted radiopharmaceutical oncology pipeline.

Scale indicators10 records

Recent moves3 records

Expansion highlights5 records

Niowave competitors and assessment

Company assessment

Direct peers

  • NorthStar Medical Radioisotopes: U.S.-based commercial producer of medical radioisotopes (notably Mo-99/Tc-99m) using accelerator and neutron-capture technology. Most directly comparable U.S. private radioisotope producer competing for the same domestic, cGMP-grade supply contracts with pharma and imaging customers.
  • SHINE Technologies: U.S. company producing medical radioisotopes including Ac-225 and lutetium-177 using fusion-based neutron sources. Direct competitor in cGMP Ac-225 supply targeting the same radioligand therapy and targeted alpha therapy developers.
  • ITM Isotope Technologies Munich: Germany-based medical radioisotope producer (notably Lu-177 and Ac-225) supplying global pharma and radiopharma developers. Direct international peer in cGMP-grade therapeutic radioisotope supply for cancer applications.
  • IBA RadioPharma Solutions: Belgium-based supplier of particle accelerators and radioisotope production solutions to nuclear medicine and radiopharma producers. Overlaps with Niowave in accelerator-based isotope production technology and end-customer relationships in the medical radioisotope supply chain.

Broad incumbents

  • Curium Pharma: Global nuclear medicine leader producing a broad portfolio of diagnostic and therapeutic radioisotopes. Overlaps with Niowave in cGMP medical isotope supply but operates at much greater scale across Mo-99, I-131, Lu-177 and other isotopes.
  • GE HealthCare (Radiopharma): Diversified medtech giant with a substantial radiopharma business spanning PET tracers, SPECT agents and emerging therapeutic isotopes. Broad incumbent offering isotope production as part of a much wider imaging and pharmaceutical portfolio.
  • Lantheus Holdings: Public radiopharmaceutical company specializing in diagnostic imaging agents and increasingly therapeutic radioligands. Comparable end-customer focus in oncology nuclear medicine, though primarily a developer/marketer rather than a pure-play isotope supplier.
  • Bayer (Radiopharmaceuticals / Algeta legacy): Major pharma with an established radioligand therapy franchise (Xofigo / Ra-223) and growing investment in targeted radionuclide therapies. A large incumbent competing for the same clinical and commercial therapeutic isotope demand.

Emerging players

  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents using Ac-225, Lu-177 and other isotopes. Significant overlap as a downstream buyer/developer of medical radioisotopes, positioning Telix as both customer and adjacent competitor in targeted alpha therapy.
  • Fusion Pharmaceuticals: Clinical-stage radioconjugate developer (now part of AstraZeneca) that has been a Niowave Ac-225 supply customer. Represents the emerging radiopharma developer peer that depends on suppliers like Niowave for isotope feedstock.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Niowave compliance and trust

Trust signal

Compliance4 records

Niowave financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Niowave leadership team

Management profile

Number of profiles

Profiles6 records

Niowave subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Niowave funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Niowave M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Niowave

What does Niowave do?

Niowave manufactures and supplies high-purity, cGMP-compliant medical radioisotopes — primarily Actinium-225 (Ac-225) and Yttrium-90 (Y-90) — using proprietary superconducting linear accelerators paired with in-house radiochemistry and hot-cell processing. The isotopes are sold under multi-year bilateral supply agreements to global pharmaceutical and biotechnology customers developing targeted alpha therapy and radioligand therapy for cancer, with the company also entering 50/50 strategic co-development collaborations (e.g., Aptevo) and operating a proprietary radium-226 acquisition/recovery program that supplies feedstock for Ac-225 production.

Is Niowave a public or private company?

Niowave is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Niowave founded?

Niowave was founded in 2005. It employs 101 to 250 people.

Where is Niowave based?

Niowave is headquartered in Lansing, United States, in the North America region.

How does Niowave make money?

Three revenue lines are on record. Long-term isotope supply agreements are the primary driver. The others are strategic co-development collaborations and private exempt securities offerings.

Who are Niowave's main competitors?

Direct peers on record are NorthStar Medical Radioisotopes, SHINE Technologies, ITM Isotope Technologies Munich and IBA RadioPharma Solutions. Broad incumbents are Curium Pharma, GE HealthCare (Radiopharma), Lantheus Holdings and Bayer (Radiopharmaceuticals / Algeta legacy). Emerging players are Telix Pharmaceuticals and Fusion Pharmaceuticals.

Does Niowave have an API?

No public API is recorded for Niowave.

What industry is Niowave in?

Niowave's product category is Medical Radioisotope Manufacturing. Its primary akta.pro industry code is EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireU.S. Labor Secretary Highlights Advanced Manufacturing and Biotech Jobs During Visit to NiowaveU.S. Labor Secretary Keith Sonderling toured Niowave's Lansing facility and the construction site of its new medical radioisotope production plant. The $85 million expansion will create at least 73 jobs with starting wages above the regional median and is expected to become operational in 2028.YahooPrism Controls expanding Vergennes Twp. facilityPrism Controls is expanding its Vergennes Township facility, doubling its 15,000-square-foot space. The expansion, supported by a $210,000 MEDC grant, will create 28 new jobs and bring $3.8 million in capital investment. The company also received support for Niowave and Geotab expansions.YahooAPVO: Focusing on Three Key Areas of DevelopmentAptevo Therapeutics said it is concentrating on three development areas: mipletamig, a 50/50 collaboration with Niowave on radiopharmaceutical oncology, and its ADAPTIR platforms. Updated RAINIER data from 31 evaluable patients showed an 87% clinical benefit rate, 81% remission rate, 55% MRD negativity and no cytokine release syndrome through Cohort 5. Aptevo expects to complete Phase 1b and select a Phase 2 dose by year-end 2026.The Pharma LetterAstraZeneca locks in long-term actinium-225 supply with NiowaveNiowave has expanded its supply agreement with AstraZeneca to a 10-year commitment for actinium-225 after the pharmaceutical company exercised an option to increase capacity. The deal aims to secure reliable supply of the scarce alpha-emitting isotope, which is critical for AstraZeneca’s growing radioconjugate pipeline targeting cancer treatments.FolhaDoadas por Marie Curie ao Brasil há cem anos, agulhas de rádio hoje são estudadas nos EUAA three-year agreement between the Brazilian National Nuclear Energy Commission (CNEN) and US pharmaceutical company Niowave involves processing historical radium-226 needles donated by Marie Curie in 1926 to produce actinium. The material, previously stored as radioactive waste in Brazil, was sent to the United States for reprocessing, with the resulting actinium intended for use in treating metastatic tumors. This partnership aims to advance radio-pharmaceutical capabilities while resolving environmental liabilities associated with the legacy radioactive sources.Quiver QuantitativeAptevo APVO Reports Q2 2026 Update With $9.8 Million Cash | APVO Stock NewsAptevo Therapeutics reported its Q2 2026 business update, revealing $9.8 million in cash and positive clinical data for mipletamig showing an 87% clinical benefit rate in frontline acute myeloid leukemia patients. The company secured a $1.5 million grant for APVO451 development and established a collaboration with Niowave to explore radiopharmaceutical oncology programs.Stock TitanAptevo 2Q26 Earnings: 87% AML Benefit RateAptevo Therapeutics reported second-quarter 2026 financial results and provided a business update highlighting strong clinical data for its lead drug mipletamig in treating acute myeloid leukemia. The company also announced a strategic 50/50 collaboration with Niowave to develop radiopharmaceutical oncology programs and secured $1.5 million in non-dilutive funding for its APVO451 candidate.FinancialContent Business PageAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial ResultsAptevo Therapeutics reported its second-quarter 2026 financial results and provided a business update highlighting strong clinical data for its lead drug mipletamig in treating acute myeloid leukemia. The company also announced the appointment of a new Chief Scientific Officer, secured $1.5 million in non-dilutive funding for its APVO451 candidate, and entered into a strategic collaboration with Niowave to develop radiopharmaceutical therapies.BioSpaceAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial ResultsAptevo reported Q2 2026 results, highlighting mipletamig's 87% clinical benefit rate in frontline AML and a path to Phase 2 in 2027. The company also secured $1.5M in non-dilutive funding for APVO451 and a 50/50 radiopharmaceutical collaboration with Niowave. Cash on hand was $9.8 million as of June 30, 2026.MorningstarAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial ResultsAptevo reported Q2 2026 results and a business update, highlighting mipletamig's 87% clinical benefit rate in frontline AML and a path to Phase 2 in 2027. The company also secured $1.5M in non-dilutive funding for APVO451 and a 50/50 radiopharmaceutical collaboration with Niowave.